A recent study suggests that patients who stop using popular GLP-1 drugs like Wegovy and Mounjaro may regain lost weight much more quickly than those who end conventional diet and exercise plans.
Published data in a major medical journal points out that while overweight people can lose substantial amounts of their body weight while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month after stopping.
"Individuals buying these medications must be aware of the risk of rapid rebound weight gain when the treatment ends," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a reversion to original mass within about 18 months.
Comparing Treatments
The analysis, which examined 37 of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with older methods.
Scientists note that people who lose weight through diet and exercise generally have a less rapid creep back—perhaps 0.1 kg a month—once they finish.
The Reason for the Rapid Rebound
Experts propose the mechanism of the drugs is key to understanding the accelerated rebound.
GLP-1 drugs mimic a body's own chemical called GLP-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels far above than the body's typical production may cause the body to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement leads to appetite is no longer kept in check, making binge eating far more likely."
An Ongoing Condition?
The NHS advise the injections for people with obesity-related health risks, accompanied by recommended lifestyle changes.
Many experts argue that, considering the likelihood of relapse, the treatment is often ongoing.
This view is supported by pharmaceutical companies, who note that the findings "highlight the chronic character of excess weight," similar to managing conditions like high blood pressure.
User Testimonies
People who have discontinued the jabs describe a sudden resurgence of appetite.
"It was like a trigger that goes on and you're instantly starving," recalled one woman.
This challenge is exacerbated if individuals have not adopted sustainable dietary or behavioural modifications during treatment.
Significant Adoption
Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is higher among females than men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, experts caution that while the jabs are potent tools for weight loss, they are not a standalone solution and lasting health benefits hinges on combined lifestyle changes.
